Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs, 2024. Verfasst von Sheridan M Hoy. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com. Hauptthemen laut MEDLINE: Primary Immunodeficiency Diseases, Drug Approval, Receptors, CXCR4. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Mavorixafor (XOLREMDI™) is an oral, selective C-X-C chemokine receptor 4 (CXCR4) antagonist developed by X4 Pharmaceuticals that blocks the binding of C-X-C chemokine ligand 12 (also known as stromal derived factor-1) to CXCR4. In April 2024, it became the first therapy to be approved for WHIM syndrome (named by an acronym for its observed characteristics of Warts, Hypogammaglobulinaemia, Infections and Myelokathexis) in the USA, where it is indicated for use in patients aged ≥ 12 years with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes. Clinical development of mavorixafor is ongoing for chronic neutropenic disorders. This article summarizes the milestones in the development of mavorixafor leading to this first approval for use in patients aged ≥ 12 years with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Zitieren
APA
Hoy, S. M. (2024). Mavorixafor: First Approval. Drugs. https://doi.org/10.1007/s40265-024-02063-y
Vancouver
Hoy SM. Mavorixafor: First Approval. Drugs. 2024. doi:10.1007/s40265-024-02063-y
BibTeX
@article{Hoy2024,
author = {Hoy, Sheridan M},
title = {Mavorixafor: First Approval},
journal = {Drugs},
year = {2024},
doi = {10.1007/s40265-024-02063-y}
}
EUVIMED